Although the rapid strides made in technology have produced increasingly targeted drugs, Mother Nature still has a lot to offer as far as medicine is concerned.
Pyridomycin, a substance produced by non-pathogenic soil bacteria, has been found to be a potent antibiotic against a related strain of bacteria that cause tuberculosis. The EPFL scientists who discovered this unexpected property now have a better understanding of how the molecule functions.
Screening Tests for Tuberculosis
Tuberculin skin test and Interferon - Release Assays are tests used to screen for tuberculosis.
Advertisement
Its complex three-dimensional structure allows it to act simultaneously on two parts of a key enzyme in the tuberculosis bacillus, and in doing so, dramatically reduce the risk that the bacteria will develop multiple resistances. The researchers, along with their colleagues at ETH Zurich, have published their results in the journal Nature Chemical Biology. Stewart Cole, director of EPFL's Global Health Iabilitynstitute, led a team that discovered the anti-tuberculosis effect of pyridomycin in 2012.
By inhibiting the action of the "InhA" enzyme, pyridomycin literally caused the thick lipid membrane of the bacterium to burst. Now the scientists understand how the molecule does this job. Dual anti-mutation ability The tuberculosis bacillus needs the InhA enzyme along with what scientists refer to as a "co-factor," which activates the enzyme, in order to manufacture its membrane. The scientists discovered that pyridomycin binds with the co-factor, neutralizing it. But pyridomycin doesn't stop there.
![Tuberculosis]( "Tuberculosis")
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to other organs.
It also blocks another element needed for making the membrane, the InhA binding site. "Researchers in the pharmaceutical industry have been looking for this weakness in the TB bacillus for decades," explains Ruben Hartkoorn, first author on the article. By binding simultaneously onto these two elements and neutralizing them, pyridomycin prevents the bacterium from generating its membrane, and it ends up bursting like a balloon. Better still, this dual action drastically reduces the risk that the bacteria will become resistant, because in order to develop resistance, two different specific mutations must exist at the same time. This is increasingly important because cases of multi-resistant TB are on the rise.
Nature's twisting paths - a lesson in efficiency "It's a powerful lesson from nature with respect to drug design," explains Cole, co-author and EPFL professor. "The three-dimensional structures of naturally occurring molecules are often more complex, more twisted, than synthetic molecules, and that's precisely what allows pyridomycin to bind onto these two sites simultaneously." In fact, it binds so effectively that the molecule is not yet ready to be used therapeutically: it doesn't last long enough in the patient's body. This is the point at which bioengineering needs to take over from Mother Nature - to develop a more robust version of the molecule. This is what the ETH team led by Karl-Heinz Altmann is working on. "Eventually we could multiply the molecule's binding sites, so that it could inhibit critical functions of other pathogenic bacteria," says Cole.
Source: Eurekalert
Tuberculosis
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to other organs.
Advertisement
It also blocks another element needed for making the membrane, the InhA binding site. "Researchers in the pharmaceutical industry have been looking for this weakness in the TB bacillus for decades," explains Ruben Hartkoorn, first author on the article. By binding simultaneously onto these two elements and neutralizing them, pyridomycin prevents the bacterium from generating its membrane, and it ends up bursting like a balloon. Better still, this dual action drastically reduces the risk that the bacteria will become resistant, because in order to develop resistance, two different specific mutations must exist at the same time. This is increasingly important because cases of multi-resistant TB are on the rise.
Nature's twisting paths - a lesson in efficiency "It's a powerful lesson from nature with respect to drug design," explains Cole, co-author and EPFL professor. "The three-dimensional structures of naturally occurring molecules are often more complex, more twisted, than synthetic molecules, and that's precisely what allows pyridomycin to bind onto these two sites simultaneously." In fact, it binds so effectively that the molecule is not yet ready to be used therapeutically: it doesn't last long enough in the patient's body. This is the point at which bioengineering needs to take over from Mother Nature - to develop a more robust version of the molecule. This is what the ETH team led by Karl-Heinz Altmann is working on. "Eventually we could multiply the molecule's binding sites, so that it could inhibit critical functions of other pathogenic bacteria," says Cole.
Source: Eurekalert
Drug Resistance - Antibiotic Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and hospital acquired diseases. Judicious use of antibiotics can control the problem.
Advertisement
Advertisement
Recommended Reading
Latest General Health News
Over 300 people had fallen sick with illness caused by Norovirus on a US cruise ship, say authorities.
Ex-smokers in Wakefield have shared their stories to encourage others to give up cigarettes on No Smoking Day 2023 which falls on 8th March.
Total levels of m6A in the nervous system rise with age and that (some) neurodegenerative diseases are characterized by RNA hypermethylation.
New study provides insights into the impact of early-life adversity on brain development and on control of reward behaviors that underlie emotional disorders
Ministry of Health of the Republic of Indonesia signed a formal memorandum of understanding (MOU) that will expand access to essential diagnostics in the country.
